Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT04511078
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Panitumumab-IRDye800 — DRUG
    single dose infusion of panitumumab-IRDye800CW

Study Details

The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.

Key Dates

Start date
Apr 2, 2021
Status verified
Dec 2025
Primary completion
Dec 31, 2030
Completion
Dec 31, 2030

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Panitumumab-IRDye800
    50 mg infusion of panitumumab-IRDye800 given over 60 minutes

Primary Outcome Measure

Tumor to background ratio of fluorescence (TBR) [ Time Frame: Day 0 through Day 15 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35233
Norma Miller, RN
[email protected]
(205) 975-6169
Jason Warram, PhD (SUB_INVESTIGATOR)

Find similar trials in Birmingham, AL

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies